Scilex Holding Company announced that it has received $101.875 million in funding from Oramed Pharmaceuticals Inc.
The company has received 101,875,000 pursuant to Regulation D and included participation from single investor.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8302 USD | -2.00% | -2.15% | -59.30% |
16/04 | Scilex Issues Preliminary Q1 Sales Results for ZTlido | MT |
20/03 | Scilex Seeks FDA Approval to Add Dosing Guidance to Gout Treatment Drug Label | MT |
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
2.38 USD | -2.06% | +1.71% | 98.46M | ||
0.8302 USD | -2.00% | -2.15% | 103M | ||
1st Jan change | Capi. | |
---|---|---|
-59.30% | 103M | |
+8.05% | 72.03B | |
-11.95% | 5.14B | |
+51.87% | 4.6B | |
+3.92% | 3.96B | |
-14.26% | 2.5B | |
+20.42% | 2.43B | |
-23.94% | 2.32B | |
+20.02% | 2.18B | |
+3.66% | 1.72B |